Provided by Tiger Fintech (Singapore) Pte. Ltd.

SINO BIOPHARM

7.370
+0.4506.50%
Volume:160.30M
Turnover:1.17B
Market Cap:138.27B
PE:35.18
High:7.430
Open:7.000
Low:6.970
Close:6.920
52wk High:9.120
52wk Low:2.634
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:2.55
T/O Rate:0.85%
Dividend:0.09
Dividend Rate:1.23%
EPS(LYR):0.210
ROE:15.40%
ROA:5.07%
PB:3.78
PE(LYR):35.18
PS:4.13

Loading ...

CMB International: CXO Sector Performance May Recover in H2, Favors SINO BIOPHARM and WUXI XDC

Deep News
·
Nov 11

Sino Biopharmaceutical Stock Advances 1.8% in Hong Kong

Dow Jones
·
Nov 10

CMB International: Healthcare Sector Favors Stable Strategies, Opportunities in Undervalued Stocks

Stock News
·
Nov 10

Sino Biopharmaceutical Stock Slides 2.4% in Hong Kong, Underperforms Competitors

Dow Jones
·
Nov 07

Sino Biopharmaceutical (HKG:1177) Could Easily Take On More Debt

Simply Wall St.
·
Nov 06

Sino Biopharmaceutical Stock Slides 2.1% in Hong Kong, Outperforms Competitors

Dow Jones
·
Nov 04

Sino Biopharmaceutical (01177) Announces October 2025 Monthly Return with No Changes in Share Capital

Bulletin Express
·
Nov 03

Sino Biopharmaceutical Stock Sheds 2.4% in Hong Kong, Outperforms Competitors

Dow Jones
·
Oct 30

Sino Biopharmaceutical Stock Advances 1.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Oct 27

Capital Flow Statistics of Hong Kong Stock Connect (T+2) | October 27

Stock News
·
Oct 27

Sino Biopharmaceutical Stock Sheds 2.7% in Hong Kong, Outperforms Competitors

Dow Jones
·
Oct 22

Hong Kong Stock Bulletin | POP MART's Overall Revenue Rises 245%-250% in Q3

Stock News
·
Oct 21

Sino Biopharm Reports Positive Phase III Results for Culmerciclib in Advanced Breast Cancer

Reuters
·
Oct 21

Does Sino Biopharm Offer Value After Jumping 135% and Expanding in Asia in 2025?

Simply Wall St.
·
Oct 19

Sino Biopharmaceutical Stock Sheds 5.0% in Hong Kong, Underperforms Competitors

Dow Jones
·
Oct 17

Zhongan International Maintains Buy Rating for SINO BIOPHARM (01177) with Target Price of HKD 9.4

Stock News
·
Oct 17

Sino Biopharm's Plexiform Neurofibromas Drug Gets Breakthrough Therapeutic Designation in China

MT Newswires Live
·
Oct 15

SINO BIOPHARM (01177): TQ-B3234 “Selective MEK1/2 Inhibitor” Included in Breakthrough Therapy Designation Program

Stock News
·
Oct 15

Sino Biopharmaceutical - Tq-B3234 Included in Breakthrough Therapy Designation Process by China's Cde

THOMSON REUTERS
·
Oct 15

Sino Biopharmaceutical Stock Climbs 1.8% in Hong Kong

Dow Jones
·
Oct 15